Stock Events

Stock Events

Defence Therapeutics 

$0.39
20
-$0.01-3.26% Today

Statistics

Day High
0.38
Day Low
0.38
52W High
1
52W Low
0.31
Volume
7,400
Avg. Volume
6,912
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

21JunExpected
Q1 2020
Q2 2020
Q3 2020
Q4 2020
Q1 2021
Q3 2021
Q1 2022
-0.1
-0.07
-0.03
-0
Expected EPS
N/A
Actual EPS
-0.037

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-5.11MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow DTCFF. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Merck
MRK
Mkt Cap214.76B
Merck & Co., Inc. is a global healthcare company that develops medications and vaccines for many of the same diseases Defence Therapeutics targets, including cancer immunotherapy.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol-Myers Squibb operates in similar therapeutic areas as Defence Therapeutics, especially in oncology and immune-oncology, making them direct competitors in the biopharmaceutical sector.
Pfizer
PFE
Mkt Cap140.15B
Pfizer Inc. is involved in the discovery, development, and manufacture of healthcare products including vaccines and treatments for immune and inflammatory diseases, competing in the same space as Defence Therapeutics.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences, Inc. focuses on the discovery, development, and commercialization of medicines in areas of unmet medical need, including oncology, competing directly with Defence Therapeutics' cancer therapies.
AMGEN
AMGN
Mkt Cap160.66B
Amgen Inc. is a biotechnology company that develops innovative human therapeutics, with a strong focus on oncology and inflammatory diseases, areas that overlap with Defence Therapeutics' focus.
Novartis
NVS
Mkt Cap237.61B
Novartis AG is a global healthcare company that operates in the research, development, manufacturing, and marketing of a wide range of healthcare products, including those in oncology and immunology, directly competing with Defence Therapeutics.
Roche
RHHBY
Mkt Cap258.9B
Roche Holding AG focuses on pharmaceuticals and diagnostics in oncology, immunology, and infectious diseases, areas that are in direct competition with Defence Therapeutics' research and product development.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca PLC is a multinational pharmaceutical and biopharmaceutical company with a strong emphasis on oncology, respiratory, cardiovascular, and metabolic diseases, competing in the same therapeutic areas as Defence Therapeutics.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson is a broad healthcare company that develops and sells pharmaceuticals, medical devices, and consumer health products, with a pharmaceutical division that competes in oncology and immunology.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions, including cancer and inflammatory diseases, competing with Defence Therapeutics.

About

Defence Therapeutics Inc., a biotechnology company, engages in the research and development of biological/biosimilar therapeutic drugs for cancer and infectious diseases. Its proprietary platform is the ACCUMTM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells. The company focuses on developing dendritic cell cancer vaccines; protein-based vaccine formulation against COVID and infectious diseases; and antibody drug conjugates (ADC) products targeting various cancers. The company was formerly known as Accum Therapeutics Inc. and changed its name to Defence Therapeutics Inc. in March 2020. Defence Therapeutics Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.
Show more...
CEO
Mr. Sebastien Plouffe
Country
CA
ISIN
CA24463V1013

Listings

F
DE
DTC.F
CN
CA
DTC.CN
OTC Link
US
DTCFF

0 Comments

Share your thoughts

FAQ

What is Defence Therapeutics stock price today?▼
The current price of DTCFF is $0.39 USD — it has decreased by -3.26% in the past 24 hours. Watch Defence Therapeutics stock price performance more closely on the chart.
What is Defence Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Defence Therapeutics stocks are traded under the ticker DTCFF.
What were Defence Therapeutics earnings last quarter?▼
DTCFF earnings for the last quarter are -0.04 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Defence Therapeutics revenue for the last year?▼
Defence Therapeutics revenue for the last year amounts to 0 USD.
What is Defence Therapeutics net income for the last year?▼
DTCFF net income for the last year is -5.11M USD.
In which sector is Defence Therapeutics located?▼
Defence Therapeutics operates in the Health Care sector.
When did Defence Therapeutics complete a stock split?▼
Defence Therapeutics has not had any recent stock splits.
Where is Defence Therapeutics headquartered?▼
Defence Therapeutics is headquartered in Montreal, CA.